Grail, Inc.

Investigation examines whether Grail's forward guidance omitted material headwinds known to management at the time

NEW YORK, March 18, 2026 /PRNewswire/ -- Grail, Inc. (NASDAQ: GRAL) lost approximately 50% of its market value after disclosing that the NHS Galleri randomized trial failed to meet its primary endpoint. Shareholders who lost money on GRAL are encouraged to submit their information now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

Levi & Korsinsky, LLP is investigating whether Grail's forward guidance during the Class Period omitted known headwinds that would have been material to investors. On the Q3 2025 earnings call (November 12, 2025), CEO Robert P. Ragusa stated: "We believe our cash runway extends into 2030, enabling us to achieve major planned clinical and regulatory milestones." On the same call, CFO Aaron Freidin narrowed cash-burn guidance to "no more than $290 million for the full year of 2025" -- framing the Company's financial position around the assumption that those milestones would be reached.

Those milestones centered on the 140,000-participant NHS Galleri study and a modular PMA submission to the FDA. The cash-runway projection and burn-rate guidance did not reference any scenario in which the NHS trial missed its primary endpoint. When that outcome was disclosed in February 2026, the stock fell approximately 50%. The guidance figures investors relied on -- $290 million burn, runway into 2030 -- had not accounted for the clinical and regulatory consequences of the trial result.

If you purchased Grail shares and suffered a loss, click here to discuss your legal rights. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com 

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

View original content to download multimedia:https://www.prnewswire.com/news-releases/levi--korsinsky-llp-grail-gral-guided-to-2030-cash-runway-while-key-trial-risk-went-unaddressed-302716948.html

SOURCE Levi & Korsinsky, LLP

Grail told investors cash burn would be no more than $290 million while guiding to milestones the Company may have known were at risk

NEW YORK, March 4, 2026 /PRNewswire/ -- Grail, Inc. (NASDAQ: GRAL) investors lost approximately half the value of their holdings when the stock plunged roughly 50% following disclosure that the NHS Galleri trial missed its primary endpoint. If you lost money on GRAL, submit your information now to discuss your legal rights. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

On the Q3 2025 earnings call on November 12, 2025, CFO Aaron Freidin told investors the Company was "updating our cash-burn guidance further to no more than $290 million for the full year of 2025." In the same remarks, CEO Robert Ragusa stated: "We believe our cash runway extends into 2030, enabling us to achieve major planned clinical and regulatory milestones." Those milestones included completion of the FDA PMA submission and full clinical-utility results from the 140,000-participant NHS Galleri study. The cash-burn figure and runway projection were presented as sufficient to fund a pathway that, following the trial's failure, may require additional studies, revised timelines, or materially different capital needs.

Shareholders who purchased GRAL shares and suffered losses are encouraged to click here to submit their information before the investigation concludes. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

Levi & Korsinsky, LLP -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

View original content to download multimedia:https://www.prnewswire.com/news-releases/gral-drops-50----reported-numbers-vs-actual-results-levi--korsinsky-llp-investigates-302704187.html

SOURCE Levi & Korsinsky, LLP